PubMed Health⌕ Search

Biomedical subjects

J G Valdivieso

Publications and source records attributed to J G Valdivieso.

4 recordsLinked to original sources
PubMed1993

Calcified brain metastasis.

Two patients with rare cases of calcified brain metastases are reported. The relatively benign clinical course and prolonged survival are stressed. The first patient had an adenocarcinoma of unknown origin with three calcified brain metastases. The patient underwent an incisional brain biopsy without radiotherapy and survived for 2 years and 9 months. The second patient had a squamous cell carcinoma of the lung with a large, solitary brain metastasis. The brain tumor was calcified and remained stable without progression for at least 4 months before surgical resection.

Adenocarcinoma↗
PubMed1986

Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy.

The antiemetic effect of graded, single high-dose intravenous dexamethasone was studied in 27 patients receiving combination chemotherapy with either doxorubicin (50 mg/m2) or cis-platinum (100 mg/m2). A total of 57 cycles were individually evaluated, utilizing a detailed rating system. Nausea and vomiting did not occur in 20 of 57 cycles; in 17, the chemotherapy was doxorubicin-based, and in 3 it was cis-platinum-based. Of the 37 cycles associated with nausea and vomiting, 32 contained cis-platinum and 5 doxorubicin. The average dexamethasone dosages for doxorubicin and platinum-containing combinations were 40 and 95 mg/m2, respectively. Side effects included a dose-dependent sensation of perineal pruritus (11 patients, 17 cycles) lasting for several minutes, and subjective feelings of increased appetite and well-being. Dexamethasone administered intravenously 15 min prior to chemotherapy in a dose of 40 mg/m2 apparently provides highly effective antiemetic protection for patients receiving treatment cycles containing doxorubicin; however, for patients receiving regimens containing cis-platinum, the antiemetic effect of dexamethasone as a single agent is limited.

Adult↗
PubMed1984

Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma.

42 consecutive patients with head and neck squamous cell carcinoma were entered into a multi-agent chemotherapy protocol including: bleomycin and Cis-platinum (in continuous infusion), sequenced with methotrexate and Vinblastine (by bolus infusion). Hydroxyurea was substituted for bleomycin when the accumulative dose of bleomycin reached 400 units. 9 of 11 patients with untreated disease responded to chemotherapy, with 36.4% showing complete response following the second cycle. After completion of all therapy, complete response had occurred in 10 patients and partial response in 1. At a median follow-up of 1 year, 9 patients are disease-free, and the median duration of response has not yet been reached. For recurrent disease, the overall regression rate is 45.1% (14/31). The median duration of response is 6.5 months, with responding patients showing a median survival of 8.7 months and non-responders, 5.4 months. The data for response and survival are comparable to previous studies and suggest that toxic manifestations may be mitigated by careful attention to nutrition and production of an anabolic state prior to therapy.

Aged↗